|
|
Article: Dynavax, Johns Hopkins University, and NIH-Sponsored Immune Tolerance Network Present New Positive Data from Phase II Study of Ragweed Immunotherapy Product (AIC); Results Suggest Extended Benefits of Therapy.
- Article from:
- PR Newswire
- Article date:
- March 11, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DENVER -- DENVER, March 11 /PRNewswire/ -- A single course of Dynavax's proprietary anti-allergy immunotherapy known as AIC appears to provide extended protection against ragweed allergy, according to Phase II clinical data presented here at the 60th annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). According to the study, AIC administration prior to the 2001 allergy season resulted in reduced allergy symptoms and other clinical markers of the allergic response through the following 2002 ragweed season, indicating a long-lasting effect of the drug. The study results were reported by Peter Creticos, M.D. of the Johns Hopkins University, ...
Related newspaper, magazine, and journal articles:
|
|
Article: CompuMed Receives Letter of Intent from Johns Hopkins ...
PR Newswire;
May 4, 1999 ;
700+ words
... ... a Letter of Intent from The Johns Hopkins University Medical School and The Johns Hopkins University Applied Physics Laboratory to cooperatively ... musculoskeletal diseases. The Johns Hopkins University Medical School (JHU) and The Johns ...
|
|